First cancer drug rejection isn’t the end

Medicare Part D appeals for cancer drugs between 2020 and 2024 resulted in approval for just under one in five cases, yet many patients fail to utilize this option despite its potential to secure necessary treatment. Research published in JAMA Network Open examined 4,952 second-level appeals—external reviews conducted after initial denials—and found a 19.5% approval rate. The highest success occurred with appeals tied to prior authorization criteria, achieving a 61% approval rate, indicating these disputes often hinge on procedural rather than clinical factors.

Reasons Behind Cancer Drug Denials

Insurance companies most frequently reject cancer drug coverage when treatments are new, labeled experimental, or used off-label, meaning for purposes beyond the FDA’s original approval. Off-label use is widespread in oncology, as drugs may demonstrate effectiveness in additional cancers or treatment combinations before formal guidelines update. Joanna Fawzy Doran, CEO of Triage Cancer, explained that denials also arise from outdated medical guidelines or insurers relying on older approval standards instead of newer evidence. Medical advancements often outpace regulatory updates.

Patients rarely accept the first denial as final. Medicare, Medicaid, employer plans, and private insurers all provide appeal pathways, though uptake remains low. This disparity reflects how insurers balance medical necessity against cost, often favoring conservative interpretations of drug effectiveness.

Mechanics of Appeals and Common Setbacks

The appeals process begins with understanding a patient’s insurance plan rules. Triage Cancer offers state-specific guides outlining steps, but patients often bear the responsibility of collecting medical evidence, drafting appeals, and following up. Healthcare providers usually handle the initial filing, arguing medical necessity based on diagnosis and treatment plans. If the first appeal fails, patients can escalate to an independent review, though this option is rarely pursued.

The length of time depends on the type of insurance you have. One place where the external appeals process is useful is the prior authorization stage. If the insurance company says no to that prior authorization, and it’s time sensitive for that patient to start treatment, you can make the argument that it’s urgent. You can file the internal and the external appeal at the same time and get a response back within 72 hours.

Delays in approvals can have deadly consequences. Many patients abandon the process due to exhaustion or financial strain. Others mistakenly believe denial means no coverage exists, unaware of external appeals as a last resort. Data show across states that very few people are using it, and when I say very few, I mean like 100 people in the whole state.

Patients should instruct their care teams to file appeals on their behalf, but communication gaps are frequent. Providers may not recognize coverage struggles, or patients may assume their doctors are already handling appeals. This requires collaboration. She recommends patients request research studies, clinical trial data, or expert letters to strengthen appeals, documentation insurers often dismiss without proper submission.

Patient Experiences with Denials

When facing a denial, patients should first verify whether the insurer cited medical necessity, experimental status, or off-label use. If a drug is FDA-approved for a different cancer but evidence supports its use in the patient’s case, providers must present that evidence clearly. Insurance policies follow guidelines, but guidelines lag behind clinical practice. A treatment may become standard before rules reflect its validity.

Read Also: Staying Fit on the Go Made Easy

The process demands significant time. Medicare’s second-level appeals can stretch for weeks, while private insurers may delay reviews for months. Patients unable to wait can file both internal and external appeals simultaneously to expedite decisions. Financial pressure worsens the issue: without coverage, patients face substantial costs. Some patients turn to clinical trials or charitable aid, but these remain temporary fixes, not lasting solutions.

Triage Cancer’s findings highlight a broader issue: most patients never appeal, assuming denial is irreversible. The 19.5% Medicare approval rate suggests the system disadvantages those who do not persist. Even when appeals succeed, insurers may impose new restrictions, such as mandatory step therapy or prior authorization for refills. The appeals process is a prolonged struggle, and patients often lack the endurance to complete it.

Advocates describe the system as intentionally discouraging appeals. Insurers often demand excessive documentation, delay responses, or shift responsibility to providers. The core challenge lies in making these rights accessible. For now, patients must know their options, compile evidence, and refuse to accept denial as final.